ID   KPCB_RAT                Reviewed;         671 AA.
AC   P68403; P04410; P04411;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   24-JUN-2015, entry version 120.
DE   RecName: Full=Protein kinase C beta type;
DE            Short=PKC-B;
DE            Short=PKC-beta;
DE            EC=2.7.11.13;
GN   Name=Prkcb; Synonyms=Pkcb, Prkcb1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS BETA-I AND BETA-II).
RX   PubMed=3755379; DOI=10.1016/0092-8674(86)90874-3;
RA   Knopf J.L., Lee M.-H., Sultzman L.A., Kriz R.W., Loomis C.R.,
RA   Hewick R.M., Bell R.M.;
RT   "Cloning and expression of multiple protein kinase C cDNAs.";
RL   Cell 46:491-502(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS BETA-I AND
RP   BETA-II).
RC   TISSUE=Brain;
RX   PubMed=2428667; DOI=10.1016/0014-5793(86)81010-9;
RA   Ono Y., Kurokawa T., Fujii T., Kawahara K., Igarashi K., Kikkawa U.,
RA   Ogita K., Nishizuka Y.;
RT   "Two types of complementary DNAs of rat brain protein kinase C.
RT   Heterogeneity determined by alternative splicing.";
RL   FEBS Lett. 206:347-352(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-I).
RC   TISSUE=Fibroblast;
RX   PubMed=3345563; DOI=10.1016/S0092-8674(88)80027-8;
RA   Housey G.M., Johnson M.D., Hsiao W.L.W., O'Brian C.A., Murphy J.P.,
RA   Kirschmeier P., Weinstein I.B.;
RT   "Overproduction of protein kinase C causes disordered growth control
RT   in rat fibroblasts.";
RL   Cell 52:343-354(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 448-671 (ISOFORM BETA-I).
RX   PubMed=3755404; DOI=10.1016/0014-5793(86)80724-4;
RA   Ono Y., Kurokawa T., Kawahara K., Nishimura O., Marumoto R.,
RA   Igarashi K., Sugino Y., Kikkawa U., Ogita K., Nishizuka Y.;
RT   "Cloning of rat brain protein kinase C complementary DNA.";
RL   FEBS Lett. 203:111-115(1986).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 448-671 (ISOFORM BETA-I).
RX   PubMed=3469647; DOI=10.1073/pnas.84.4.1065;
RA   Housey G.M., O'Brian C.A., Johnson M.D., Kirschmeier P.,
RA   Weinstein I.B.;
RT   "Isolation of cDNA clones encoding protein kinase C: evidence for a
RT   protein kinase C-related gene family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:1065-1069(1987).
RN   [6]
RP   PROTEIN SEQUENCE OF 500-520 AND 636-663 (ISOFORM BETA-II), AND
RP   PHOSPHORYLATION AT THR-500; THR-642 AND SER-661.
RX   PubMed=8749392; DOI=10.1016/S0960-9822(95)00277-6;
RA   Keranen L.M., Dutil E.M., Newton A.C.;
RT   "Protein kinase C is regulated in vivo by three functionally distinct
RT   phosphorylations.";
RL   Curr. Biol. 5:1394-1403(1995).
RN   [7]
RP   PHOSPHORYLATION AT SER-16; THR-17; THR-314; THR-324; THR-635 AND
RP   THR-642, AND MUTAGENESIS OF 16-SER-THR-17; THR-314; THR-324; THR-635
RP   AND THR-642.
RX   PubMed=8327493; DOI=10.1073/pnas.90.13.6130;
RA   Zhang J., Wang L., Petrin J., Bishop W.R., Bond R.W.;
RT   "Characterization of site-specific mutants altered at protein kinase C
RT   beta 1 isozyme autophosphorylation sites.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:6130-6134(1993).
RN   [8]
RP   PHOSPHORYLATION AT THR-642 (ISOFORM BETA-I), AND MUTAGENESIS OF
RP   THR-635 AND THR-642.
RX   PubMed=8034726;
RA   Zhang J., Wang L., Schwartz J., Bond R.W., Bishop W.R.;
RT   "Phosphorylation of Thr642 is an early event in the processing of
RT   newly synthesized protein kinase C beta 1 and is essential for its
RT   activation.";
RL   J. Biol. Chem. 269:19578-19584(1994).
RN   [9]
RP   PHOSPHORYLATION AT THR-500, AND MUTAGENESIS OF THR-500.
RX   PubMed=7961692;
RA   Orr J.W., Newton A.C.;
RT   "Requirement for negative charge on 'activation loop' of protein
RT   kinase C.";
RL   J. Biol. Chem. 269:27715-27718(1994).
RN   [10]
RP   FUNCTION IN INSULIN SIGNALING.
RX   PubMed=10938109; DOI=10.1128/MCB.20.17.6323-6333.2000;
RA   Formisano P., Oriente F., Fiory F., Caruso M., Miele C., Maitan M.A.,
RA   Andreozzi F., Vigliotta G., Condorelli G., Beguinot F.;
RT   "Insulin-activated protein kinase Cbeta bypasses Ras and stimulates
RT   mitogen-activated protein kinase activity and cell proliferation in
RT   muscle cells.";
RL   Mol. Cell. Biol. 20:6323-6333(2000).
RN   [11]
RP   FUNCTION IN INSULIN SIGNALING.
RX   PubMed=11714718; DOI=10.1074/jbc.M109647200;
RA   Kaneto H., Suzuma K., Sharma A., Bonner-Weir S., King G.L., Weir G.C.;
RT   "Involvement of protein kinase C beta 2 in c-myc induction by high
RT   glucose in pancreatic beta-cells.";
RL   J. Biol. Chem. 277:3680-3685(2002).
RN   [12]
RP   FUNCTION.
RX   PubMed=19176525; DOI=10.1074/jbc.M808719200;
RA   Yamasaki T., Takahashi A., Pan J., Yamaguchi N., Yokoyama K.K.;
RT   "Phosphorylation of activation transcription factor-2 at serine 121 by
RT   protein kinase c controls c-Jun-mediated activation of
RT   transcription.";
RL   J. Biol. Chem. 284:8567-8581(2009).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 157-288 IN COMPLEX WITH
RP   CALCIUM IONS.
RX   PubMed=9817842; DOI=10.1016/S0969-2126(98)00139-7;
RA   Sutton R.B., Sprang S.R.;
RT   "Structure of the protein kinase Cbeta phospholipid-binding C2 domain
RT   complexed with Ca2+.";
RL   Structure 6:1395-1405(1998).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (4.00 ANGSTROMS) OF 1-661 IN COMPLEX WITH
RP   CALCIUM IONS, AND PHOSPHORYLATION AT THR-500; THR-642 AND SER-661.
RX   PubMed=21215369; DOI=10.1016/j.cell.2010.12.013;
RA   Leonard T.A., Rozycki B., Saidi L.F., Hummer G., Hurley J.H.;
RT   "Crystal structure and allosteric activation of protein kinase C
RT   betaII.";
RL   Cell 144:55-66(2011).
CC   -!- FUNCTION: Calcium-activated, phospholipid- and diacylglycerol
CC       (DAG)-dependent serine/threonine-protein kinase involved in
CC       various cellular processes such as regulation of the B-cell
CC       receptor (BCR) signalosome, oxidative stress-induced apoptosis,
CC       androgen receptor-dependent transcription regulation, insulin
CC       signaling and endothelial cells proliferation. Plays a key role in
CC       B-cell activation by regulating BCR-induced NF-kappa-B activation.
CC       Mediates the activation of the canonical NF-kappa-B pathway
CC       (NFKB1) by direct phosphorylation of CARD11/CARMA1 at 'Ser-559',
CC       'Ser-644' and 'Ser-652'. Phosphorylation induces CARD11/CARMA1
CC       association with lipid rafts and recruitment of the BCL10-MALT1
CC       complex as well as MAP3K7/TAK1, which then activates IKK complex,
CC       resulting in nuclear translocation and activation of NFKB1. Plays
CC       a direct role in the negative feedback regulation of the BCR
CC       signaling, by down-modulating BTK function via direct
CC       phosphorylation of BTK at 'Ser-180', which results in the
CC       alteration of BTK plasma membrane localization and in turn
CC       inhibition of BTK activity. Involved in apoptosis following
CC       oxidative damage: in case of oxidative conditions, specifically
CC       phosphorylates 'Ser-36' of isoform p66Shc of SHC1, leading to
CC       mitochondrial accumulation of p66Shc, where p66Shc acts as a
CC       reactive oxygen species producer. Acts as a coactivator of
CC       androgen receptor (ANDR)-dependent transcription, by being
CC       recruited to ANDR target genes and specifically mediating
CC       phosphorylation of 'Thr-6' of histone H3 (H3T6ph), a specific tag
CC       for epigenetic transcriptional activation that prevents
CC       demethylation of histone H3 'Lys-4' (H3K4me) by LSD1/KDM1A. In
CC       insulin signaling, may function downstream of IRS1 in muscle cells
CC       and mediate insulin-dependent DNA synthesis through the RAF1-
CC       MAPK/ERK signaling cascade. May participate in the regulation of
CC       glucose transport in adipocytes by negatively modulating the
CC       insulin-stimulated translocation of the glucose transporter
CC       SLC2A4/GLUT4. Under high glucose in pancreatic beta-cells, is
CC       probably involved in the inhibition of the insulin gene
CC       transcription, via regulation of MYC expression. In endothelial
CC       cells, activation of PRKCB induces increased phosphorylation of
CC       RB1, increased VEGFA-induced cell proliferation, and inhibits
CC       PI3K/AKT-dependent nitric oxide synthase (NOS3/eNOS) regulation by
CC       insulin, which causes endothelial dysfunction. Also involved in
CC       triglyceride homeostasis (By similarity). Phosphorylates ATF2
CC       which promotes cooperation between ATF2 and JUN, activating
CC       transcription. {ECO:0000250, ECO:0000269|PubMed:10938109,
CC       ECO:0000269|PubMed:11714718, ECO:0000269|PubMed:19176525}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC       Note=Binds 3 Ca(2+) ions per subunit. The ions are bound to the C2
CC       domain.;
CC   -!- ENZYME REGULATION: Classical (or conventional) PKCs (PRKCA, PRKCB
CC       and PRKCG) are activated by calcium and diacylglycerol (DAG) in
CC       the presence of phosphatidylserine. Three specific sites; Thr-500
CC       (activation loop of the kinase domain), Thr-642 (turn motif) and
CC       Ser-661 (hydrophobic region), need to be phosphorylated for its
CC       full activation. Specifically inhibited by enzastaurin (LY317615)
CC       (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with PDK1. Interacts in vitro with PRKCBP1.
CC       Interacts with PHLPP1 and PHLPP2; both proteins mediate its
CC       dephosphorylation. Interacts with KDM1A/LSD1, PKN1 and ANDR (By
CC       similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       P18052:Ptpra (xeno); NbExp=3; IntAct=EBI-397072, EBI-6597520;
CC       Q8WV44-2:TRIM41 (xeno); NbExp=3; IntAct=EBI-397092, EBI-726015;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus {ECO:0000250}. Membrane;
CC       Peripheral membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Beta-I;
CC         IsoId=P68403-1, P04410-1;
CC         Sequence=Displayed;
CC       Name=Beta-II;
CC         IsoId=P68403-2, P04410-2;
CC         Sequence=VSP_004739;
CC   -!- PTM: Phosphorylation on Thr-500 of isoform beta-I, within the
CC       activation loop, renders it competent to autophosphorylate.
CC       Subsequent autophosphorylation of Thr-642 maintains catalytic
CC       competence, and autophosphorylation on Ser-661 appears to release
CC       the kinase into the cytosol. Similarly, isoform beta-II is
CC       autophosphorylated on 'Thr-641' and 'Ser-660', subsequent to
CC       phosphorylation on Thr-500. Autophosphorylated on other sites i.e.
CC       in the N-terminal and hinge regions have no effect on enzyme
CC       activity. Phosphorylation at Tyr-662 by SYK induces binding with
CC       GRB2 and contributes to the activation of MAPK/ERK signaling
CC       cascade. {ECO:0000269|PubMed:21215369, ECO:0000269|PubMed:7961692,
CC       ECO:0000269|PubMed:8327493, ECO:0000269|PubMed:8749392}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 AGC-kinase C-terminal domain.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 C2 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00041}.
CC   -!- SIMILARITY: Contains 2 phorbol-ester/DAG-type zinc fingers.
CC       {ECO:0000255|PROSITE-ProRule:PRU00226}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M13706; AAA41875.1; -; mRNA.
DR   EMBL; K03485; AAA41864.1; -; mRNA.
DR   EMBL; K03486; AAA41865.1; -; mRNA.
DR   EMBL; X04439; CAA28035.1; -; Genomic_DNA.
DR   EMBL; X04440; CAA28036.1; -; mRNA.
DR   EMBL; M19007; AAA41868.1; -; mRNA.
DR   EMBL; X04139; CAA27756.1; -; mRNA.
DR   EMBL; M15522; AAA41876.1; -; mRNA.
DR   PIR; A00622; KIRTC1.
DR   RefSeq; NP_001165776.1; NM_001172305.1.
DR   RefSeq; NP_036845.3; NM_012713.3.
DR   UniGene; Rn.91118; -.
DR   PDB; 1A25; X-ray; 2.70 A; A/B=154-289.
DR   PDB; 3PFQ; X-ray; 4.00 A; A=1-661.
DR   PDBsum; 1A25; -.
DR   PDBsum; 3PFQ; -.
DR   ProteinModelPortal; P68403; -.
DR   SMR; P68403; 37-668.
DR   BioGrid; 247103; 11.
DR   IntAct; P68403; 4.
DR   MINT; MINT-4099933; -.
DR   STRING; 10116.ENSRNOP00000016417; -.
DR   BindingDB; P68403; -.
DR   ChEMBL; CHEMBL2094266; -.
DR   PaxDb; P68403; -.
DR   PRIDE; P68403; -.
DR   GeneID; 25023; -.
DR   KEGG; rno:25023; -.
DR   UCSC; RGD:3396; rat.
DR   CTD; 5579; -.
DR   RGD; 3396; Prkcb.
DR   eggNOG; COG0515; -.
DR   HOGENOM; HOG000233022; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; P68403; -.
DR   KO; K02677; -.
DR   PhylomeDB; P68403; -.
DR   Reactome; REACT_271500; Response to elevated platelet cytosolic Ca2+.
DR   Reactome; REACT_296726; VEGFR2 mediated cell proliferation.
DR   Reactome; REACT_298397; Depolymerisation of the Nuclear Lamina.
DR   Reactome; REACT_318052; Activation of NF-kappaB in B cells.
DR   Reactome; REACT_326235; Disinhibition of SNARE formation.
DR   Reactome; REACT_332836; WNT5A-dependent internalization of FZD4.
DR   Reactome; REACT_342336; Trafficking of GluR2-containing AMPA receptors.
DR   Reactome; REACT_342580; G alpha (z) signalling events.
DR   EvolutionaryTrace; P68403; -.
DR   NextBio; 605147; -.
DR   PRO; PR:P68403; -.
DR   Proteomes; UP000002494; Unplaced.
DR   ExpressionAtlas; P68403; baseline and differential.
DR   Genevisible; P68403; RN.
DR   GO; GO:0031526; C:brush border membrane; IDA:RGD.
DR   GO; GO:0005813; C:centrosome; IDA:RGD.
DR   GO; GO:0005829; C:cytosol; IDA:RGD.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:RGD.
DR   GO; GO:0050681; F:androgen receptor binding; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003682; F:chromatin binding; ISS:UniProtKB.
DR   GO; GO:0042393; F:histone binding; ISS:UniProtKB.
DR   GO; GO:0035403; F:histone kinase activity (H3-T6 specific); ISS:UniProtKB.
DR   GO; GO:0030374; F:ligand-dependent nuclear receptor transcription coactivator activity; ISS:UniProtKB.
DR   GO; GO:0004697; F:protein kinase C activity; IDA:RGD.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0042113; P:B cell activation; ISS:UniProtKB.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0018894; P:dibenzo-p-dioxin metabolic process; IEP:RGD.
DR   GO; GO:0035408; P:histone H3-T6 phosphorylation; ISS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; NAS:RGD.
DR   GO; GO:0010829; P:negative regulation of glucose transport; ISS:UniProtKB.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0050861; P:positive regulation of B cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; ISS:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0042488; P:positive regulation of odontogenesis of dentin-containing tooth; IEP:RGD.
DR   GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0014059; P:regulation of dopamine secretion; IMP:RGD.
DR   GO; GO:0040008; P:regulation of growth; IMP:RGD.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0042493; P:response to drug; IMP:RGD.
DR   GO; GO:0045471; P:response to ethanol; IEP:RGD.
DR   GO; GO:0009749; P:response to glucose; IEP:RGD.
DR   GO; GO:0033280; P:response to vitamin D; IEP:RGD.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.150; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR014375; Protein_kinase_C_a/b/g.
DR   InterPro; IPR002290; Ser/Thr_dual-sp_kinase.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00130; C1_1; 2.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000550; PKC_alpha; 1.
DR   PRINTS; PR00360; C2DOMAIN.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Adaptive immunity; Alternative splicing;
KW   Apoptosis; ATP-binding; Calcium; Chromatin regulator;
KW   Complete proteome; Cytoplasm; Direct protein sequencing; Immunity;
KW   Kinase; Membrane; Metal-binding; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transcription;
KW   Transcription regulation; Transferase; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P05771}.
FT   CHAIN         2    671       Protein kinase C beta type.
FT                                /FTId=PRO_0000055687.
FT   DOMAIN      173    260       C2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00041}.
FT   DOMAIN      342    600       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      601    671       AGC-kinase C-terminal.
FT   ZN_FING      36     86       Phorbol-ester/DAG-type 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   ZN_FING     101    151       Phorbol-ester/DAG-type 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   NP_BIND     348    356       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    466    466       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   METAL       186    186       Calcium 1; via carbonyl oxygen.
FT   METAL       187    187       Calcium 1.
FT   METAL       187    187       Calcium 2.
FT   METAL       193    193       Calcium 2.
FT   METAL       246    246       Calcium 1.
FT   METAL       246    246       Calcium 2.
FT   METAL       247    247       Calcium 2; via carbonyl oxygen.
FT   METAL       248    248       Calcium 1.
FT   METAL       248    248       Calcium 2.
FT   METAL       248    248       Calcium 3.
FT   METAL       251    251       Calcium 3.
FT   METAL       252    252       Calcium 3; via carbonyl oxygen.
FT   METAL       254    254       Calcium 1.
FT   METAL       254    254       Calcium 3.
FT   BINDING     371    371       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000250|UniProtKB:P05771}.
FT   MOD_RES      16     16       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:8327493}.
FT   MOD_RES      17     17       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:8327493}.
FT   MOD_RES     250    250       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     314    314       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:8327493}.
FT   MOD_RES     324    324       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:8327493}.
FT   MOD_RES     500    500       Phosphothreonine; by PDPK1.
FT                                {ECO:0000305|PubMed:21215369,
FT                                ECO:0000305|PubMed:7961692,
FT                                ECO:0000305|PubMed:8749392}.
FT   MOD_RES     504    504       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P05771}.
FT   MOD_RES     635    635       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:8327493}.
FT   MOD_RES     642    642       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:21215369,
FT                                ECO:0000269|PubMed:8327493,
FT                                ECO:0000269|PubMed:8749392}.
FT   MOD_RES     661    661       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:21215369,
FT                                ECO:0000269|PubMed:8749392}.
FT   MOD_RES     662    662       Phosphotyrosine; by SYK. {ECO:0000250}.
FT   VAR_SEQ     622    671       RDKRDTSNFDKEFTRQPVELTPTDKLFIMNLDQNEFAGFSY
FT                                TNPEFVINV -> CGRNAENFDRFFTRHPPVLTPPDQEVIR
FT                                NIDQSEFEGFSFVNSEFLKPEVKS (in isoform
FT                                Beta-II). {ECO:0000303|PubMed:2428667,
FT                                ECO:0000303|PubMed:3755379}.
FT                                /FTId=VSP_004739.
FT   MUTAGEN      16     17       ST->AA: No effect.
FT                                {ECO:0000269|PubMed:8327493}.
FT   MUTAGEN     314    314       T->A: No effect; when associated with A-
FT                                323. {ECO:0000269|PubMed:8327493}.
FT   MUTAGEN     324    324       T->A: No effect; when associated with A-
FT                                313. {ECO:0000269|PubMed:8327493}.
FT   MUTAGEN     500    500       T->E: 50% increase of enzymatic activity.
FT                                {ECO:0000269|PubMed:7961692}.
FT   MUTAGEN     500    500       T->S: 50% decrease of enzymatic activity.
FT                                {ECO:0000269|PubMed:7961692}.
FT   MUTAGEN     500    500       T->V,D: Loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:7961692}.
FT   MUTAGEN     635    635       T->A: Loss of enzymatic activity; when
FT                                associated with T-643 change in
FT                                subcellular location, loss of PMA-induced
FT                                down-regulation and loss of enzymatic
FT                                activity. {ECO:0000269|PubMed:8034726,
FT                                ECO:0000269|PubMed:8327493}.
FT   MUTAGEN     642    642       T->A: Loss of enzymatic activity; when
FT                                associated with T-636 change in
FT                                subcellular location, loss of PMA-induced
FT                                down-regulation and loss of enzymatic
FT                                activity. {ECO:0000269|PubMed:8034726,
FT                                ECO:0000269|PubMed:8327493}.
FT   CONFLICT     25     25       A -> P (in Ref. 3; AAA41868).
FT                                {ECO:0000305}.
FT   CONFLICT    126    126       I -> V (in Ref. 1; AAA41875).
FT                                {ECO:0000305}.
FT   CONFLICT    138    138       N -> S (in Ref. 1; AAA41875).
FT                                {ECO:0000305}.
FT   CONFLICT    141    141       K -> R (in Ref. 1; AAA41875).
FT                                {ECO:0000305}.
FT   CONFLICT    149    149       S -> G (in Ref. 1; AAA41875).
FT                                {ECO:0000305}.
FT   CONFLICT    164    164       I -> V (in Ref. 1; AAA41875).
FT                                {ECO:0000305}.
FT   CONFLICT    170    171       RE -> GG (in Ref. 1; AAA41875).
FT                                {ECO:0000305}.
FT   CONFLICT    174    174       I -> V (in Ref. 1; AAA41875).
FT                                {ECO:0000305}.
FT   CONFLICT    294    294       G -> E (in Ref. 3; AAA41868).
FT                                {ECO:0000305}.
FT   CONFLICT    419    419       V -> M (in Ref. 2; CAA28035/CAA28036).
FT                                {ECO:0000305}.
FT   CONFLICT    628    628       Missing (in Ref. 1; AAA41865).
FT                                {ECO:0000305}.
FT   CONFLICT    640    640       Missing (in Ref. 1; AAA41865).
FT                                {ECO:0000305}.
FT   STRAND      161    182       {ECO:0000244|PDB:1A25}.
FT   STRAND      194    202       {ECO:0000244|PDB:1A25}.
FT   STRAND      222    230       {ECO:0000244|PDB:1A25}.
FT   HELIX       234    237       {ECO:0000244|PDB:1A25}.
FT   STRAND      239    246       {ECO:0000244|PDB:1A25}.
FT   STRAND      249    251       {ECO:0000244|PDB:1A25}.
FT   STRAND      254    262       {ECO:0000244|PDB:1A25}.
FT   HELIX       263    266       {ECO:0000244|PDB:1A25}.
FT   STRAND      271    276       {ECO:0000244|PDB:1A25}.
FT   HELIX       280    283       {ECO:0000244|PDB:1A25}.
SQ   SEQUENCE   671 AA;  76751 MW;  A1935030F758513C CRC64;
     MADPAAGPPP SEGEESTVRF ARKGALRQKN VHEVKNHKFT ARFFKQPTFC SHCTDFIWGF
     GKQGFQCQVC CFVVHKRCHE FVTFSCPGAD KGPASDDPRS KHKFKIHTYS SPTFCDHCGS
     LLYGLIHQGM KCDTCMMNVH KRCVMNVPSL CGTDHTERRG RIYIQAHIDR EVLIVVVRDA
     KNLVPMDPNG LSDPYVKLKL IPDPKSESKQ KTKTIKCSLN PEWNETFRFQ LKESDKDRRL
     SVEIWDWDLT SRNDFMGSLS FGISELQKAG VDGWFKLLSQ EEGEYFNVPV PPEGSEGNEE
     LRQKFERAKI GQGTKAPEEK TANTISKFDN NGNRDRMKLT DFNFLMVLGK GSFGKVMLSE
     RKGTDELYAV KILKKDVVIQ DDDVECTMVE KRVLALPGKP PFLTQLHSCF QTMDRLYFVM
     EYVNGGDLMY HIQQVGRFKE PHAVFYAAEI AIGLFFLQSK GIIYRDLKLD NVMLDSEGHI
     KIADFGMCKE NIWDGVTTKT FCGTPDYIAP EIIAYQPYGK SVDWWAFGVL LYEMLAGQAP
     FEGEDEDELF QSIMEHNVAY PKSMSKEAVA ICKGLMTKHP GKRLGCGPEG ERDIKEHAFF
     RYIDWEKLER KEIQPPYKPK ARDKRDTSNF DKEFTRQPVE LTPTDKLFIM NLDQNEFAGF
     SYTNPEFVIN V
//
